SCHEMBL21766015

SCHEMBL21766015

Cc1cccc(CNC(=O)C2CCN(S(=O)(=O)c3cc(Cl)cc(Cl)c3)CC2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 2/20 0.65
KMT2A Q03164 3/20 0.56
GAA P10253 2/20 0.56
MEN1 O00255 1/20 0.56
PKM P14618 3/20 0.55
PLA2G1B P04054 1/20 0.55
ATG4B Q9Y4P1 1/20 0.55
RECQL P46063 1/20 0.55
APOBEC3A P31941 1/20 0.55
APOBEC3G Q9HC16 1/20 0.55
ALDH1A1 P00352 2/20 0.54
USP2 O75604 1/20 0.53
ALOX15 P16050 1/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
EPHX2 P34913 2/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22423586 0.90 SLC13A5 (0.67) SLC13A5KMT2AGAAMEN1PKM
SCHEMBL21766071 0.84 GAA (0.79) SLC13A5KMT2AGAAMEN1PKM
SCHEMBL21766054 0.82 SLC13A5 (0.62) SLC13A5KMT2AGAAPKMPLA2G1B
SCHEMBL21765924 0.82 SLC13A5 (0.65) SLC13A5KMT2AGAAMEN1PKM
SCHEMBL21766050 0.81 SLC13A5 (0.76) SLC13A5KMT2AALDH1A1TSHRTP53
SCHEMBL20258778 0.81 PKM (0.69) SLC13A5GAAPKMPLA2G1BATG4B
SCHEMBL21766074 0.81 SLC13A5 (0.72) SLC13A5KMT2AGAAMEN1PKM
SCHEMBL21766068 0.81 SLC13A5 (0.85) SLC13A5KMT2AMEN1PKMPLA2G1B
SCHEMBL20258781 0.80 PKM (0.74) SLC13A5KMT2AGAAMEN1PKM
SCHEMBL21766055 0.79 SLC13A5 (0.76) SLC13A5KMT2AGAAPKMPLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793522-B2 Sulfonamides as inhibitors of the uptake of extracellular citrate BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-06 US disclosed
US-20200062708-A1 SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE BOEHRINGER INGELHEIM PHARMA GBMH & CO KG (DE) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062708-A1 SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE CS, GLS, GLS2 SLC13A5 261/4885KMT2A 3613/4885GAA 102/4885
US-10793522-B2 Sulfonamides as inhibitors of the uptake of extracellular citrate CS, GLS, GLS2 SLC13A5 261/4885KMT2A 3613/4885GAA 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.